1.	Phase III Randomized Study of Paclitaxel in Combination With Cisplatin or Topotecan Hydrochloride With Versus Without Bevacizumab in Patients With Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0240, GOG-0240, NCT00803062
2.	Phase II Study of Whole Body Hyperthermia Combined With Doxorubicin HCl Liposome and Fluorouracil in Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UTHSC-MS-96205, NCI-V97-1356, NCT00003135
3.	Phase II Study of Isotretinoin, Interferon alfa-2b, and Paclitaxel in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CINJ-100101, NJ 1703, CINJ-3390, CINJ-NJ1703, NCT00138151
4.	Phase II Study of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: GOG-0222, NCT00217633
5.	Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-01-111, HSC-MS-01-111, NCT00178802
6.	Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 06US03IMP-852A [Cooley], MT2006-02, NCT00319748
7.	Phase II Pilot Study of Irradiated Allogeneic Related Donor Lymphocyte Infusion in Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
8.	Phase II Study of Cetuximab in Patients With Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GOG-0227E, GOG-0227E, BMS-CA225-275, NCT00499031
9.	Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-1098, GSK 107278, NCT00548418
10.	Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2007-0324, NCT00626561
11.	Phase II Study of Pemetrexed Disodium and Cisplatin in Patients With Advanced, Persistent, or Recurrent Carcinoma of the Cervix Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: NCI Protocol IDs: GOG-0076GG, GOG-0076GG, NCT00691301
12.	Phase II Trial of BIBW 2992 in Genetically Pre-Screened Cancers With EGFR and/or HER2 Gene Amplification. Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.26, NCT00748709
13.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
14.	Phase II Study of Ixabepilone in Patients With Unresectable Recurrent Cervical Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-09-C-0037, 09-C-0037, 6620, NCT00798928
15.	Phase I Study of UCN-01 and Irinotecan in Patients With Resistant Solid Tumors or Locally Recurrent or Metastatic Breast Cancer (Part I Closed to Accrual as of 6/8/2007) Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: WUSM-SCC-0102, NCI-5582, 5582, NCT00031681
16.	Phase I Study of BB-10901 in Patients With Relapsed or Refractory Small Cell Lung Cancer, Other Pulmonary Tumors of Neuroendocrine Origin, Non-Pulmonary Small Cell Carcinoma, Metastatic Carcinoid Tumors, or Other CD56-Positive Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IMMUNO-C10/IVB/002, IMMUNO-002, MDA-2004-0557, NCT00346385
17.	Phase I Study Using Sunitinib Plus Radiation Therapy for Cancer Patients Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06C.549, NCT00437372
18.	A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UCIRB 15424A, NCT00523432
19.	Phase I Study of 1-methyl-d-tryptophan in Patients With Relapsed or Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: VU-VICC-PHI-0814, VICCPHI0814, NLGC-NLG-2100, IRB#080257, VICTR-1855, NCT00788086
20.	Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TAMC 3H04, NCT00160472
21.	Chemoradiation-Induced Nausea and Emesis: Quality of Life Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2003-0529, NCT00394602
22.	Respiratory Tumor and Normal Tissue Motion Phase: No phase specified Type: Natural history/Epidemiology, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2003-0962, NCT00415675